Safety and Efficacy of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

Study Overview
=================
Brief Summary
-----------------
The study is designed to collect safety and efficacy of Desferasirox in Chinese patients with Iron Overload and Aplastic Anemia.

Official Title
-----------------
A Single Arm, Multicenter, Open Label Study of Desferasirox in Chinese Patients With Iron Overload and Aplastic Anemia

Conditions
-----------------
Iron Overload

Intervention / Treatment
-----------------
* Drug: Desferasirox


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients presenting with transfusion-related IOL as shown by a SF level of ≥ 1000 ng/mL at start of study History of transfusion >20 international units or 100 mL/kg of red blood cells Underlying transfusion-dependent illness: AA: Clinically diagnosed AA with bone marrow confirmation of the diagnosis Age ≥ 18 years, male or female Written informed consent obtained from patient prior to any screening procedures. Exclusion Criteria: Patients with serum creatinine > ULN or with significant proteinuria as indicated by a urinary protein/creatinine ratio (UPCR) ≥ 1.0 mg/mg in a non-first void urine sample at baseline. If serum creatinine is found to be > ULN or UPCR is found to be ≥ 1 mg/mg the test can be repeated after 1 month. Creatinine Clearance <40 ml/min Patients with other than AA transfusion-dependent underlying illnesses Patients with a previous history of clinically relevant ocular and/or auditory toxicity related to iron chelation Any other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of any drug. The investigator should be guided by evidence of any of the following: history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal bleeding history of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection history of pancreatic injury or pancreatitis; indications of impaired pancreatic function/injury as indicated by abnormal lipase or amylase history or presence of impaired renal function as indicated by creatinine or blood urea nitrogen (BUN) values equal or above ULN history of urinary obstruction or difficulty in voiding Other protocol-defined inclusion/exclusion criteria may apply

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Desferasirox<br> | Drug: Desferasirox<br>* Initial Dose: 20 mg/kg/d. Dose modification according to protocol.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in serum ferritin from baseline to 52 weeks with desferasirox treatment in Chinese patients with AA presenting with transfusional hemosiderosis and pre-existing serum ferritin levels of ≥ 1000 ng/mL. | Difference in serum ferritin from baseline vs. 52 weeks of treatment. | Every 4 Weeks for 52 weeks of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between serum ferritin (SF) and transferrin saturation (TFS) | Study will compare SF with TFS level to find degree of relationship measured by correlation. | Every 4 Weeks for 52 weeks of treatment | 
| Number of dispensed, used, partially used or unused packages of study medication to assess drug usage compliance |  | Every 4 Weeks for 52 weeks of treatment | 
| Correlation between dose adjustment (increase or decrease) regimens and transfusional burden | Evaluation of the relationship between dose adjustment regimens (as dictated by both efficacy and safety parameters) and transfusional burden will be undertaken. | Every 3 months for 52 Weeks of treatment | 
| Number of patients with adverse events, serious adverse events and death |  | Every 4 weeks for 52 Weeks of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Phase 4, Desferasirox, Iron Overload, Aplastic Anemia